Physician profile
Alexander Meyer
NPI 1639533359
$2,093.05
in general payments reported to CMS, 2019-2025
19 companies · $36.47 in 2025
The $36.47 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.55 · 2022: $363 · 2023: $850 · 2024: $796 · 2025: $36.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $992.25 | 2022-2025 | Avvigo Guidance System, Opticross, Rotapro |
| Astrazeneca Pharmaceuticals Lp | $304.19 | 2022 | |
| Abiomed | $112.69 | 2023-2024 | Impella |
| Shockwave Medical, INC | $111.61 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $91.33 | 2023 | Micra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.74 | 2021-2024 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $59.88 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $48.43 | 2023-2024 | Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.60 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $36.74 | 2023-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $33.02 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $28.44 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $27.88 | 2024 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $26.20 | 2024 | Evkeeza |
| Edwards Lifesciences Corporation | $22.32 | 2023 | Sapien 3 Ultra Resilia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $21.82 | 2024 | Kengreal |
| Actelion Pharmaceuticals US, INC. | $21.02 | 2023 | Uptravi, Opsumit |
| Biosense Webster, INC. | $16.46 | 2023 | Carto 3 |
| Cardiva Medical, INC. | $14.43 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.